Efficacy and safety of 2 mg/Day of M100907 [volinanserin] on sleep maintenance insomnia with a sub-study of the effect of M100907 on stable type II diabetes mellitus: a 12-week, multi-center, randomized, double-blind, placebo-controlled study.
Phase of Trial: Phase III
Latest Information Update: 28 May 2016
At a glance
- Drugs Volinanserin (Primary)
- Indications Sleep maintenance insomnia
- Focus Therapeutic Use
- Acronyms SAMS12
- 29 Sep 2009 Actual patient number (848) added as reported by ClinicalTrials.gov.
- 12 Nov 2008 Status changed from active, no longer recruiting to completed, as reported in ClinicalTrials.gov.
- 14 Sep 2008 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.